Why Is Aurora Cannabis (TSX:ACB) Burning Through Cash?

Nearly all cannabis companies continue to burn cash to meet the fast-growing demand for recreational and medical marijuana. Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB) used a mix of cash and stock to fund its acquisitions.

| More on:
Double exposure of a businessman and stairs - Business Success Concept

Image source: Getty Images

Recreational marijuana became legal in Canada in October 2018. The hysteria surrounding the industry was unprecedented before and after. But the high returns it promised did not eventuate, leaving investors shocked and awed. The major cannabis companies were showing little or no profit but were burning cash like crazy.

All industries go through birth pains, and the marijuana business is no exception. However, this fast-paced industry also represents big money. Enormous amounts of cash are needed to ramp up production, acquire other cannabis companies, and expand internationally. So, a cannabis company needs deep pockets.

So many millions of dollars are being spent, in fact, that only a few cannabis companies might survive to see the light of day. Let’s look at the massive spending undertaken by Aurora Cannabis (TSX:ACB)(NYSE:ACB).

Bold moves

This soon-to-be-the-largest cannabis producer grew big via an aggressive M&A strategy. Aurora made several equity investments in various cannabis companies. The most notable was the hostile takeover of a competitor called CanniMed Therapeutics.

The deal was concluded in January 2018 at a cost of $1.1 billion. Aurora paid $1.7 million in cash, and roughly 3.4 million of its own shares. This high-profile purchase propelled Aurora into the limelight.

Soon afterwards, the company made the strategic decision to buy MedReleaf for $3.2 billion in an all-stock transaction. But a problem in using the company’s own stocks is shareholder dilution. Luckily, Aurora’s stock price soared after the CanniMed transaction and made shareholders happy.

The subsequent merger with MedReleaf brought less satisfaction. This time, the shareholders did not benefit from the dilution. Aurora pursued more acquisitions, including 25% of Green Organic Dutchman, and 52.7% of Hempco, Alcanna, and Radient Technology.

Besides these costly purchases, Aurora has several subsidiaries including Pedanios, the largest cannabis distributor in Germany; CanvasRx, Canada’s largest outreach service for medical cannabis patients; and BC Northern Lights, an indoor growing supplies manufacturer.

You can also count a world-leading greenhouse engineering and design consultancy firm (Aurora-Larssen) and a late-stage ACMPR applicant in Quebec (H2 Biopharma).

Premium weed stock in the making

Aurora bought firms by diluting shareholders, because the company has no wealthy institutional partner to bankroll its purchases. But it seems all Aurora’s moves have turned out for the better. The recent acquisitions will help the company produce a powerful portfolio of brands. When that happens, Aurora’s position in the cannabis space will be second to none.

Aurora is also hoping to gain a solid foothold in the medical marijuana market, along with the recreational one, since the margins are higher on the medical side. With the largest global presence, Aurora will be able to sell the higher-valued cannabis products in countries where the demand is strong.

According to strategic adviser Nelson Peltz, Aurora Cannabis is moving closer to generating positive EBITDA. Will investors finally make profits on the stock? Maybe, but I’m not prepared to recommend a strong buy. Some analysts predict Aurora’s price will double in the next few months. This would mean it hasn’t burned cash for nothing.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned.

More on Cannabis Stocks

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

A close up image of Canadian $20 Dollar bills
Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why This Little-Known Cannabis Stock Could Double in 2024

This cannabis stock has already doubled this year since 52-week lows and could easily rise that much once more.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 420-Foot Pole

Down 87% from all-time highs, Cronos Group stock is a still a high-risk investment for long-term shareholders in 2024.

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth: Buy, Sell, or Hold?

Canopy Growth (TSX:WEED) stock should make a killing on U.S. expansion, but investors will need to be very patient.

Read more »

Marijuana plant and cannabis oil bottles isolated
Energy Stocks

3 Canadian Value Stocks to Buy Right Now

Undervalued Canadian stocks such as Secure Energy should be part of your shopping list in May 2024.

Read more »